Background: Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan is highly effective in treating limb-threatening soft tissue sarcoma (STS) and other bulky tumors. Because of fear of TNF-associated toxicity, ILP with TNF is not offered to older patients in some cancer centers, although especially in older patients, every attempt to avoid an amputation that may end their independence must be considered.
Isolated limb perfusion (ILP) is a technique of cancer treatment that delivers high doses of cytostatic drugs to a tumor-bearing extremity that is isolated from the systemic circulation and connected to a heart-lung machine. 1 By ILP, regional concentrations of chemotherapeutic agents 15 to 20 times higher than those reached after systemic administration can be achieved without systemic toxicity. 2 In the management of locally advanced soft tissue sarcoma (STS), limb salvage is a major challenge. In patients with multiple and/or bulky in-transit melanoma metastases, obtaining local control is a major challenge. In contrast to the inefficacy of ILP with melphalan alone in the management of irresectable extremity STS, with response rates of only 10% to 35%, 3,4 the introduction of tumor necrosis factor-␣ (TNF) in combination with melphalan in ILP has been reported in a European multicenter trial; it resulted in response rates Ͼ80% and limb-salvage rates Ͼ70% in STS. 5, 6 These results led to the approval of TNF in Europe. 7 Also, in the management of in-transit metastases, TNF seems to improve complete response (CR) rates, 8 especially in patients with bulky tumors and in patients whose previous ILP with melphalan alone failed, as has been demonstrated by reports from the Surgery Branch of the National Cancer Institute in the United States. 9, 10 The incidence of STS increases rapidly above the age of 50 years. Approximately 18% of the patient population is above the age of 70 years. 4 The incidence of malignant melanoma has more than doubled over the last 20 years. 12 For both men and women, rates increased relatively more in the older age groups. As a consequence of these epidemiological features, we are confronted with a large group of elderly patients who might need a limb-saving procedure such as ILP. These pa-tients, especially, will be severely limited in their mobility and lose independence when amputation of a limb has to be performed. Therefore, especially in the elderly, every attempt to avoid amputation must be considered, and a TNF-based ILP must be considered despite the age of the patients. The perception that TNF-based ILP is a risky endeavor has been demonstrated to be false provided that leakage is monitored and well controlled. 13 But even in the event of significant leakage, we have demonstrated that with correct fluid management and postoperative care, patients do not develop major or life-threatening complications. 14 Therefore we do not think it is reasonable to consider age a limiting factor for patients to undergo a TNF-based ILP. Here we present our single Rotterdam institution experience in a large series of patients aged Ͼ75 years with irresectable STS or in-transit melanoma metastases of an extremity. These patients were all treated by ILP with high-dose TNF and melphalan.
PATIENTS AND METHODS

ILP Methodology
We have described the procedure of the current TNFbased ILP previously. 1,2 In brief, isolation of the blood circuit of a limb is achieved by clamping and cannulating the major artery and vein, connecting to an oxygenated extracorporeal circuit, ligating collateral vessels, and applying a tourniquet. Once isolation is secured, drugs can be injected into the perfusion circuit.
Drugs
Recombinant human TNF-␣ (4.9 -5.8 ϫ 10 7 U/mg) was administered at doses of 2 to 4 mg in the perfusion circuit; recombinant human interferon-␥ (IFN␥; .2 mg or 1.5 ϫ 10 6 U/ampoule) was administered in the ILPs performed in the period 1991 to 1993 on days Ϫ2 and Ϫ1 subcutaneously and on day 0 into the perfusion circuit. Both TNF and IFN␥ were obtained from Boehringer Ingelheim GmbH (Ingelheim/Rhein, Germany). Melphalan (L-phenylalanine mustard; Alkeran™; Burroughs Wellcome, London, UK) was obtained as a sterile powder (100 mg) that was dissolved aseptically by using solvent and diluent provided by Burroughs Wellcome (London, UK). Because of its efficacy and low regional toxicity profile, melphalan is the standard drug, most commonly used at a dose of 10 mg/L of perfused tissue for a leg and 13 mg/L for an arm. The perfusate is heated to 39°C to 40°C to achieve mild hyperthermia tissue temperatures in the limbs, to be kept stable at 39°C. Radiolabeled albumen is injected into the extracorporeal circuit so that leakage into the systemic circulation can be detected with a precordial scintillation probe. 15 Leakage monitoring is mandatory, especially now that high doses of TNF are used in the treatment of STS and melanomas. After 1.5 hours of perfusion, the limb is rinsed with an electrolyte solution, cannulas are removed, and the vessels are repaired. Classification of postoperative limb toxicity was performed according to Wieberdink et al. 16 : grade I, no reaction; grade II, slight erythema, edema, or both; grade III, considerable erythema and/or edema with some blistering, slightly disturbed motility permissible; grade IV, extensive epidermolysis and/or obvious damage to the deep tissues, causing definite functional disturbances; threatening or manifest compartmental syndrome; and grade V, reaction that may necessitate amputation.
Patients
At the Erasmus University Medical Center-Daniel den Hoed Cancer Center, 306 TNF-based ILPs were performed in STS patients (224 ILPs) and melanoma patients (82 ILPs) between 1991 and 2001. In 43 patients (14 men and 29 women) older than 75 years, 50 TNFbased ILPs were performed. Twelve patients also received .2 mg of IFN␥ subcutaneously on the 2 days before the ILP as well as .2 mg of IFN␥ in the perfusion circuit during ILP. All ILP and follow-up data in our institution are recorded prospectively in a database. Patient and ILP characteristics, treatment results, and follow-up data are listed in Table 1 for STS or other nonmelanoma limb-threatening tumors and in Table 2 for melanoma. The mean age of this selected group of patients was 79 years (range, 75-91 years). Twenty-nine patients with irresectable STS or other limb-threatening tumors of the leg (n ϭ 19) or arm (n ϭ 10) underwent 34 ILPs (Table 1) . Nineteen were treated for primary tumors and 10 for recurrences. In this group, the median size of single tumors (n ϭ 20) was 10 cm (range, 6 -38 cm), and for multifocal tumors (n ϭ 9) it was 5 cm (range, 1-20 cm). Two patients with Stewart-Treves syndrome had undergone three ILPs each. One patient underwent two perfusions. Fourteen patients with in-transit melanoma metastases (all lower extremity) underwent 16 ILPs (Table 2). Two patients underwent two ILPs.
RESULTS
Sarcomas and Nonmelanoma Limb-Threatening Tumors
In the STS group, all patients but two (postoperative deaths) were evaluated for response by magnetic resonance imaging (MRI) and histopathologic evaluation of the tumor resection specimen after response to the ILP.
